234 related articles for article (PubMed ID: 17914095)
21. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
22. Polymorphism analysis of CYP3A5 in myeloid leukemia.
Liu TC; Lin SF; Chen TP; Chang JG
Oncol Rep; 2002; 9(2):327-9. PubMed ID: 11836601
[TBL] [Abstract][Full Text] [Related]
23. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades.
Nikoleishvili D; Pertia A; Tsintsadze O; Gogokhia N; Chkhotua A
Georgian Med News; 2007 Feb; (143):34-8. PubMed ID: 17404436
[TBL] [Abstract][Full Text] [Related]
25. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.
Avgeris M; Koutalellis G; Fragoulis EG; Scorilas A
Clin Biochem; 2008 Oct; 41(14-15):1140-9. PubMed ID: 18586020
[TBL] [Abstract][Full Text] [Related]
26. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance].
Liu BQ; Wu YD; Wei JX; Zhang T; Liu RL; Ma TX
Zhonghua Nan Ke Xue; 2007 Nov; 13(11):997-1001. PubMed ID: 18077911
[TBL] [Abstract][Full Text] [Related]
27. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Chua CW; Chiu YT; Yuen HF; Chan KW; Man K; Wang X; Ling MT; Wong YC
Clin Cancer Res; 2009 Jul; 15(13):4322-35. PubMed ID: 19509141
[TBL] [Abstract][Full Text] [Related]
28. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.
Dai Y; Hebert MF; Isoherranen N; Davis CL; Marsh C; Shen DD; Thummel KE
Drug Metab Dispos; 2006 May; 34(5):836-47. PubMed ID: 16501005
[TBL] [Abstract][Full Text] [Related]
29. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population.
Quaranta S; Chevalier D; Bourgarel-Rey V; Allorge D; Solas C; Lo-Guidice JM; Sampol-Manos E; Vacher-Coponat H; Moal V; Broly F; Lhermitte M; Lacarelle B
Toxicol Lett; 2006 Jul; 164(2):177-84. PubMed ID: 16442753
[TBL] [Abstract][Full Text] [Related]
30. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients.
Faria PC; Saba K; Neves AF; Cordeiro ER; Marangoni K; Freitas DG; Goulart LR
Cancer Invest; 2007 Dec; 25(8):726-32. PubMed ID: 18058470
[TBL] [Abstract][Full Text] [Related]
32. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR.
Finnström N; Bjelfman C; Söderström TG; Smith G; Egevad L; Norlén BJ; Wolf CR; Rane A
Eur J Clin Invest; 2001 Oct; 31(10):880-6. PubMed ID: 11737226
[TBL] [Abstract][Full Text] [Related]
33. Genotyping cytochrome P450 3A5 using the Light Cycler.
Fredericks S; Moreton M; MacPhee IA; Mohamed M; Marlowe S; Jorga A; Johnston A; Carter ND; Holt DW
Ann Clin Biochem; 2005 Sep; 42(Pt 5):376-81. PubMed ID: 16168193
[TBL] [Abstract][Full Text] [Related]
34. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome p450 and glutathione s-transferase mRNA expression in human fetal liver hematopoietic stem cells.
Shao J; Stapleton PL; Lin YS; Gallagher EP
Drug Metab Dispos; 2007 Jan; 35(1):168-75. PubMed ID: 17050647
[TBL] [Abstract][Full Text] [Related]
36. Selective metabolism of vincristine in vitro by CYP3A5.
Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism.
Doherty D; Dvorkin SA; Rodriguez EP; Thompson PD
Prostate; 2014 Feb; 74(3):273-85. PubMed ID: 24242708
[TBL] [Abstract][Full Text] [Related]
38. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
39. Fingerprinting the diseased prostate: associations between BPH and prostate cancer.
Shah US; Getzenberg RH
J Cell Biochem; 2004 Jan; 91(1):161-9. PubMed ID: 14689588
[TBL] [Abstract][Full Text] [Related]
40. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
